TLK-286: a novel glutathione S-transferase-activated prodrug.

  title={TLK-286: a novel glutathione S-transferase-activated prodrug.},
  author={Kenneth D. Tew},
  journal={Expert opinion on investigational drugs},
  volume={14 8},
  • Kenneth D. Tew
  • Published 2005 in Expert opinion on investigational drugs
Telik, Inc. (Palo Alto, CA, USA) is currently developing TLK-286, a novel prodrug that is preferentially activated by glutathione S-transferase P1-1 (GST-pi). TLK-286 is the lead clinical candidate from a group of rationally designed glutathione analogues designed to exploit high GST-pi levels in solid tumours and drug-resistant cell populations. This concept was based on extensive literature showing that the overexpression of GST-pi in human tumours is associated with malignancy, poor… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 25 extracted citations

Similar Papers

Loading similar papers…